JP2016512558A - ヒト免疫不全ウイルス複製の阻害剤 - Google Patents
ヒト免疫不全ウイルス複製の阻害剤 Download PDFInfo
- Publication number
- JP2016512558A JP2016512558A JP2016501870A JP2016501870A JP2016512558A JP 2016512558 A JP2016512558 A JP 2016512558A JP 2016501870 A JP2016501870 A JP 2016501870A JP 2016501870 A JP2016501870 A JP 2016501870A JP 2016512558 A JP2016512558 A JP 2016512558A
- Authority
- JP
- Japan
- Prior art keywords
- tert
- butoxy
- mmol
- acetic acid
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361781764P | 2013-03-14 | 2013-03-14 | |
| US61/781,764 | 2013-03-14 | ||
| PCT/US2014/025525 WO2014159959A1 (en) | 2013-03-14 | 2014-03-13 | Inhibitors of human immunodeficiency virus replication |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016512558A true JP2016512558A (ja) | 2016-04-28 |
| JP2016512558A5 JP2016512558A5 (enExample) | 2017-03-09 |
Family
ID=50842317
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016501870A Pending JP2016512558A (ja) | 2013-03-14 | 2014-03-13 | ヒト免疫不全ウイルス複製の阻害剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9527842B2 (enExample) |
| EP (1) | EP2970274B1 (enExample) |
| JP (1) | JP2016512558A (enExample) |
| CN (1) | CN105189503B (enExample) |
| ES (1) | ES2623904T3 (enExample) |
| WO (1) | WO2014159959A1 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015123230A1 (en) * | 2014-02-12 | 2015-08-20 | Bristol-Myers Squibb Company | Benzothiazole macrocycles as inhibitors of human immunodeficiency virus replication |
| WO2015126765A1 (en) | 2014-02-19 | 2015-08-27 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| US9193720B2 (en) | 2014-02-20 | 2015-11-24 | Bristol-Myers Squibb Company | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| US9975906B2 (en) | 2014-05-16 | 2018-05-22 | Shionogi & Co., Ltd. | Tricyclic heterocycle derivatives having HIV replication inhibitory effect |
| JP6614585B2 (ja) | 2015-05-29 | 2019-12-04 | 塩野義製薬株式会社 | Ｈｉｖ複製阻害作用を有する含窒素３環性誘導体 |
| CA2990575A1 (en) | 2015-07-06 | 2017-01-12 | VIIV Healthcare UK (No.5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| RU2018102554A (ru) | 2015-07-08 | 2019-08-08 | ВАЙВ ХЕЛТКЕР ЮКей (N5) ЛИМИТЕД | Производные пиридин-3-ил уксусной кислоты в качестве ингибиторов репликации вируса иммунодефицита человека |
| BR112018000253A2 (pt) | 2015-07-09 | 2018-09-04 | Viiv Healthcare Uk No 5 Ltd | composto, composição, e, método para tratar a infecção pelo hiv. |
| EP3319954A1 (en) | 2015-07-09 | 2018-05-16 | VIIV Healthcare UK (No.5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| WO2017025864A1 (en) | 2015-08-07 | 2017-02-16 | VIIV Healthcare UK (No.5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| CA2994517A1 (en) | 2015-08-10 | 2017-02-16 | VIIV Healthcare UK (No.5) Limited | Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication |
| AR105653A1 (es) | 2015-08-11 | 2017-10-25 | VIIV HEALTHCARE UK (Nº 5) LTD | Derivados del ácido 5-(n-bencil-tetrahidroisoquinolin-6-il)-piridin-3-il acético como inhibidores de la replicación del virus de la inmunodeficiencia humana |
| JP2018522909A (ja) | 2015-08-12 | 2018-08-16 | ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド | ヒト免疫不全ウイルス複製の阻害剤としての５−（ｎ−縮合三環式アリールテトラヒドロイソキノリン−６−イル）ピリジン−３−イル酢酸誘導体 |
| TW201718537A (zh) | 2015-08-12 | 2017-06-01 | Ｖｉｉｖ醫療保健英國（Ｎｏ．５）有限公司 | 做為人類免疫缺陷病毒複製抑制劑之吡啶－３－基乙酸衍生物 |
| RU2018106501A (ru) | 2015-08-12 | 2019-09-13 | ВАЙВ ХЕЛТКЕР ЮКей (N5) ЛИМИТЕД | Производные 5-(N-[6,5]-конденсированный бицикличный арил-тетрагидроизохинолин-6-ил)-пиридин-3-ил-уксусной кислоты в качестве ингибиторов репликации вируса иммунодефицита человека |
| AU2016307987B2 (en) | 2015-08-20 | 2018-08-30 | VIIV Healthcare UK (No.5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| WO2017070089A1 (en) | 2015-10-19 | 2017-04-27 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| DK3377488T3 (da) | 2015-11-19 | 2022-10-03 | Incyte Corp | Heterocykliske forbindelser som immunomodulatorer |
| SG10202005790VA (en) | 2015-12-22 | 2020-07-29 | Incyte Corp | Heterocyclic compounds as immunomodulators |
| WO2017192961A1 (en) | 2016-05-06 | 2017-11-09 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| US10407410B2 (en) | 2016-05-11 | 2019-09-10 | VIIV Healthcare UK (No.5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| US20190152957A1 (en) | 2016-05-11 | 2019-05-23 | VIIV Healthcare UK (No.5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| EP3455217A1 (en) | 2016-05-11 | 2019-03-20 | ViiV Healthcare UK (No.5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| MA45116A (fr) | 2016-05-26 | 2021-06-02 | Incyte Corp | Composés hétérocycliques comme immunomodulateurs |
| BR112018076534A2 (pt) | 2016-06-20 | 2019-04-02 | Incyte Corporation | compostos heterocíclicos como imunomoduladores |
| MA45669A (fr) | 2016-07-14 | 2019-05-22 | Incyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
| ES2941716T3 (es) | 2016-08-29 | 2023-05-25 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| EP3558985B1 (en) | 2016-12-22 | 2022-09-07 | Incyte Corporation | Benzooxazole derivatives as immunomodulators |
| MD3558990T2 (ro) | 2016-12-22 | 2023-02-28 | Incyte Corp | Derivați tetrahidro imidazo[4,5-c]piridină ca inductori de internalizare a PD-L1 |
| WO2018119221A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Pyridine derivatives as immunomodulators |
| WO2018119236A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Triazolo[1,5-a]pyridine derivatives as immunomodulators |
| EP3558963B1 (en) | 2016-12-22 | 2022-03-23 | Incyte Corporation | Bicyclic heteroaromatic compounds as immunomodulators |
| EP3565809A1 (en) | 2017-01-03 | 2019-11-13 | ViiV Healthcare UK (No.5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| JP2020503352A (ja) | 2017-01-03 | 2020-01-30 | ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド | ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−３−イル酢酸誘導体 |
| US11779637B2 (en) | 2017-04-24 | 2023-10-10 | Nantcell, Inc. | Targeted neoepitope vectors and methods therefor |
| HRP20230090T1 (hr) | 2018-03-30 | 2023-03-17 | Incyte Corporation | Heterociklički spojevi kao imunomodulatori |
| PT3790877T (pt) | 2018-05-11 | 2023-05-10 | Incyte Corp | Derivados de tetrahidro-imidazo[4,5-c]piridina como imunomoduladores pd-l1 |
| WO2019244066A2 (en) | 2018-06-19 | 2019-12-26 | VIIV Healthcare UK (No.5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| WO2020003093A1 (en) | 2018-06-25 | 2020-01-02 | VIIV Healthcare UK (No.5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| AR119624A1 (es) | 2019-08-09 | 2021-12-29 | Incyte Corp | Sales de un inhibidor de pd-1 / pd-l1 |
| MX2022003578A (es) | 2019-09-30 | 2022-05-30 | Incyte Corp | Compuestos de pirido[3,2-d]pirimidina como inmunomoduladores. |
| IL292524A (en) | 2019-11-11 | 2022-06-01 | Incyte Corp | Salts and crystalline forms of a pd-1/pd-l1 inhibitor |
| CR20230230A (es) | 2020-11-06 | 2023-07-27 | Incyte Corp | Proceso para hacer un inhibidor de pd-1/pdl1 y sales y formas cristalinas del mismo |
| WO2022099018A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Process of preparing a pd-1/pd-l1 inhibitor |
| US11760756B2 (en) | 2020-11-06 | 2023-09-19 | Incyte Corporation | Crystalline form of a PD-1/PD-L1 inhibitor |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012033735A1 (en) * | 2010-09-08 | 2012-03-15 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| JP2012526728A (ja) * | 2009-05-15 | 2012-11-01 | ギリアード サイエンシス インコーポレーテッド | ヒト免疫不全ウイルス複製の阻害剤 |
| WO2013025584A1 (en) * | 2011-08-18 | 2013-02-21 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7939545B2 (en) | 2006-05-16 | 2011-05-10 | Boehringer Ingelheim International Gmbh | Inhibitors of human immunodeficiency virus replication |
| PT2220076E (pt) | 2007-11-15 | 2012-04-26 | Gilead Sciences Inc | Inibidores da replicação do vírus da imunodeficiência humana |
| NZ585297A (en) | 2007-11-15 | 2012-06-29 | Gilead Sciences Inc | Inhibitors of human immunodeficiency virus replication |
| BRPI0820307A2 (pt) | 2007-11-16 | 2019-09-24 | Boehringer Ingelheim Int | inibidores de replicação do vírus da imunodeficiência humana |
| US8461180B2 (en) | 2007-11-16 | 2013-06-11 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
| US8353602B2 (en) | 2007-11-23 | 2013-01-15 | Koninklijke Philips Electronics N.V. | Compartment |
| GB0908394D0 (en) | 2009-05-15 | 2009-06-24 | Univ Leuven Kath | Novel viral replication inhibitors |
| GB0913636D0 (en) | 2009-08-05 | 2009-09-16 | Univ Leuven Kath | Novel viral replication inhibitors |
| ES2475970T3 (es) | 2009-12-23 | 2014-07-11 | Katholieke Universiteit Leuven | Novedosos compuestos antivirales |
| PE20130385A1 (es) | 2010-07-02 | 2013-03-30 | Gilead Sciences Inc | Derivados del acido naft-2-ilacetico para tratar el sida |
| PT2588455T (pt) | 2010-07-02 | 2018-06-29 | Gilead Sciences Inc | Derivados de ácido 2-quinolinil-acético como compostos antivirais para vih |
| AU2011330850B2 (en) | 2010-11-15 | 2016-01-28 | Viiv Healthcare Uk Limited | Inhibitors of HIV replication |
| WO2012065963A2 (en) | 2010-11-15 | 2012-05-24 | Katholieke Universiteit Leuven | Novel antiviral compounds |
-
2014
- 2014-03-13 EP EP14727271.0A patent/EP2970274B1/en not_active Not-in-force
- 2014-03-13 ES ES14727271.0T patent/ES2623904T3/es active Active
- 2014-03-13 US US14/773,223 patent/US9527842B2/en not_active Expired - Fee Related
- 2014-03-13 WO PCT/US2014/025525 patent/WO2014159959A1/en not_active Ceased
- 2014-03-13 CN CN201480027109.2A patent/CN105189503B/zh not_active Expired - Fee Related
- 2014-03-13 JP JP2016501870A patent/JP2016512558A/ja active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012526728A (ja) * | 2009-05-15 | 2012-11-01 | ギリアード サイエンシス インコーポレーテッド | ヒト免疫不全ウイルス複製の阻害剤 |
| WO2012033735A1 (en) * | 2010-09-08 | 2012-03-15 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| WO2013025584A1 (en) * | 2011-08-18 | 2013-02-21 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105189503A (zh) | 2015-12-23 |
| EP2970274A1 (en) | 2016-01-20 |
| ES2623904T3 (es) | 2017-07-12 |
| US9527842B2 (en) | 2016-12-27 |
| EP2970274B1 (en) | 2017-03-01 |
| CN105189503B (zh) | 2017-03-22 |
| WO2014159959A1 (en) | 2014-10-02 |
| US20160024077A1 (en) | 2016-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016512558A (ja) | ヒト免疫不全ウイルス複製の阻害剤 | |
| US8906929B2 (en) | Inhibitors of human immunodeficiency virus replication | |
| US9580431B2 (en) | Inhibitors of human immunodeficiency virus replication | |
| EP2822950B1 (en) | Inhibitors of human immunodeficiency virus replication | |
| US8629276B2 (en) | Inhibitors of human immunodeficiency virus replication | |
| US8791108B2 (en) | Inhibitors of human immunodeficiency virus replication | |
| AU2016297558A1 (en) | Colony stimulating factor-1 receptor (CSF-1R) inhibitors | |
| EP3186254B1 (en) | Imidazo[1,2-a]pyridine derivatives for use as inhibitors of human immunodeficiency virus replication | |
| JP2016516692A (ja) | ヒト免疫不全ウイルス複製の阻害剤 | |
| EP3116880B1 (en) | Pyridin-3-yl acetic acid macrocycles as inhibitors of human immunodeficiency virus replication | |
| US9932356B2 (en) | Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication | |
| WO2015126743A1 (en) | Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication | |
| EP3114129A1 (en) | Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication | |
| EP3105236B1 (en) | Benzothiazole macrocycles as inhibitors of human immunodeficiency virus replication | |
| US9932353B2 (en) | Imidazopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication | |
| JP2018519348A (ja) | ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−３−イル酢酸誘導体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20160219 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170131 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170131 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20171212 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20171221 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180116 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20180807 |